SIALANAR

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, UK.

Active ingredients

The drug SIALANAR contains one active pharmaceutical ingredient (API):

1	Glycopyrronium UNII H4S7L81L98 - CHLOROGLYCOPYRRONIUM BROMIDE
	Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.
	Read more about Glycopyrronium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SIALANAR Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A03AB02	Glycopyrronium bromide	A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AB Synthetic anticholinergics, quaternary ammonium compounds
Discover more medicines within A03AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1729155, 1798139
FI	Lääkealan turvallisuus- ja kehittämiskeskus	171056
FR	Base de données publique des médicaments	62719472
GB	Medicines & Healthcare Products Regulatory Agency	337308, 366848
IE	Health Products Regulatory Authority	30800
IT	Agenzia del Farmaco	045092018, 045092020
LT	Valstybinė vaistų kontrolės tarnyba	1081083, 1087548
NL	Z-Index G-Standaard, PRK	199109
PL	Rejestru Produktów Leczniczych	100377641
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69128001, W69128002